Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVOPHED vs EPHEDRINE SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.
Treatment of hypotension in acute hypotensive states (e.g., septic shock, myocardial infarction, blood loss),Adjunct in the treatment of cardiac arrest (off-label)
Treatment of hypotension during spinal anesthesia,Bronchodilation in asthma (less common),Nasal congestion (topical use),Off-label: Treatment of shock, myasthenia gravis (with neostigmine)
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Terminal elimination half-life 3-6 hours in adults with normal renal function; prolonged in renal impairment or alkaline urine.
Primarily metabolized in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Ephedrine is metabolized primarily by oxidative deamination via monoamine oxidase (MAO) and also by N-demethylation via CYP450 isoenzymes, though specific CYP enzymes are not well characterized. It has a half-life of 3–6 hours.
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Renal excretion of unchanged drug (60-70%) and minor metabolites; small amount biliary; p H-dependent; acidic urine enhances elimination.
Approximately 25-30% bound to albumin and other plasma proteins.
~20-30% bound, primarily to albumin.
Approximately 0.7-1.0 L/kg. This indicates moderate distribution into tissues and plasma, consistent with a hydrophilic catecholamine.
~2-3 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier.
Bioavailability is 100% via intravenous administration. Oral bioavailability is negligible due to extensive first-pass metabolism; not administered orally. Intramuscular or subcutaneous administration results in erratic absorption and significant vasoconstriction leading to poor bioavailability; thus, intravenous infusion is the only reliable route.
Oral: ~85% (first-pass metabolism minimal); IM/SC: nearly 100%.
No specific dose adjustment required for renal impairment; titrate to clinical response.
GFR 10-50 m L/min: administer 75% of normal dose every 6 hours. GFR <10 m L/min: administer 50% of normal dose every 6 hours.
No specific dose adjustment required for hepatic impairment; titrate to clinical response.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use or use with extreme caution, reduce dose by 75%.
Initial: 0.05-0.1 mcg/kg/min IV continuous infusion, titrate to effect; maximum dose not established.
Oral: 3 mg/kg/day divided every 4-6 hours. Parenteral: 0.2-0.3 mg/kg/dose intramuscularly or subcutaneously every 4-6 hours; intravenous: 0.05-0.2 mg/kg/dose every 5-10 minutes as needed.
Start at lower end of dosing range (2-4 mcg/min IV) due to increased sensitivity and comorbidities; titrate cautiously.
Initiate at lower doses (e.g., 25 mg orally every 4-6 hours) due to increased sensitivity and risk of CNS stimulation and cardiovascular effects; monitor blood pressure and heart rate closely.
No FDA boxed warning exists for LEVOPHED.
None.
Risk of extravasation leading to tissue necrosis; ensure proper IV access and avoid infiltration,Monitor blood pressure, heart rate, and cardiac output continuously,May cause ischemia to limbs, kidneys, and splanchnic organs due to vasoconstriction,Use with caution in patients with hypertension, hyperthyroidism, or myocardial ischemia,Abrupt discontinuation may cause rebound hypotension
Cardiovascular effects: hypertension, tachycardia, arrhythmias,Central nervous system stimulation: anxiety, insomnia, tremor,Tachyphylaxis with repeated use,Exacerbation of narrow-angle glaucoma,Use in patients with cardiovascular disease, hyperthyroidism, diabetes, or prostatic hypertrophy requires caution
Hypersensitivity to norepinephrine or any component of the formulation,Hypovolemia (should be corrected before or during therapy),Use with cyclopropane or halothane anesthesia (increases risk of ventricular arrhythmias),Severe peripheral vascular disease with risk of gangrene
Hypersensitivity to ephedrine or other sympathomimetics,Severe hypertension or coronary artery disease,Concurrent use with MAO inhibitors (MAOIs),Narrow-angle glaucoma,Pheochromocytoma,Hypertrophic obstructive cardiomyopathy
No clinically significant food interactions. Monitor for hyperglycemia in diabetic patients due to alpha-adrenergic effects.
Avoid excessive caffeine intake (coffee, tea, colas) as it may increase stimulant effects and risk of cardiovascular side effects. Limit or avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. No other significant food interactions.
Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental blood flow due to maternal vasoconstriction may cause fetal hypoxia and bradycardia. Use only if clearly needed, and monitor fetal heart rate. FDA Pregnancy Category C.
Ephedrine sulfate crosses the placenta. Use in the first trimester is associated with a small increased risk of gastroschisis. In the second and third trimesters, it may cause fetal tachycardia and uterine artery vasoconstriction, potentially leading to reduced uteroplacental blood flow. Animal studies have shown embryotoxicity at high doses.
Norepinephrine is not expected to be excreted into breast milk in clinically significant amounts due to its short half-life and rapid metabolism. M/P ratio not established. Use with caution in breastfeeding women, as effects on the infant are unknown.
Ephedrine is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 2.5. At therapeutic doses, it is unlikely to cause adverse effects in the infant, but irritability and disturbed sleep have been reported. Caution is advised.
Pregnancy may alter the pharmacokinetics of norepinephrine, but specific dose adjustments are not established. Monitor maternal blood pressure closely and titrate to the lowest effective dose to maintain adequate uteroplacental perfusion. Starting dose is typically 0.5-1 mcg/min, titrated to effect.
Pregnancy does not significantly alter ephedrine pharmacokinetics. However, due to increased plasma volume and renal blood flow, the volume of distribution may be slightly increased. No routine dose adjustment is required, but careful titration is recommended due to altered vascular reactivity.
LEVOPHED (norepinephrine) is a first-line vasopressor for septic shock. Administer via central line to avoid extravasation injury; if extravasation occurs, treat with phentolamine 5-10 mg in 10 m L saline infiltrated locally. Titrate to mean arterial pressure (MAP) ≥ 65 mm Hg. Taper gradually to avoid rebound hypotension.
Ephedrine sulfate is a direct and indirect sympathomimetic used primarily for hypotension during spinal/epidural anesthesia. It crosses the placenta and may cause fetal tachycardia. Avoid in patients with narrow-angle glaucoma, hyperthyroidism, or pheochromocytoma. Tachyphylaxis can develop with repeated doses. Use with caution in patients with cardiovascular disease, hypertension, or diabetes. Monitor blood pressure and heart rate closely.
This medication is used to treat dangerously low blood pressure.,It will be given intravenously (IV) in a hospital setting by healthcare professionals.,You may feel anxiety, headache, or heart palpitations as the medication works.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the medication abruptly; it must be tapered under medical supervision.
Do not take this medication without your doctor's approval if you have high blood pressure, heart disease, or thyroid problems.,Avoid using other stimulants or decongestants while on this medication.,Report any chest pain, irregular heartbeat, or shortness of breath to your healthcare provider immediately.,This medication may cause dizziness or nervousness; avoid driving or operating heavy machinery until you know how it affects you.,If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using ephedrine.
No interactions on record
"Sevoflurane, a volatile halogenated anesthetic, sensitizes the myocardium to the arrhythmogenic effects of catecholamines such as ephedrine. This synergistic action can precipitate ventricular arrhythmias, including premature ventricular contractions, bigeminy, or, rarely, ventricular tachycardia, particularly in patients with underlying cardiac disease or electrolyte imbalances. Clinically, this interaction may manifest as intraoperative arrhythmias, hemodynamic instability, or increased perioperative cardiac risk."
"The combined use of ephedrine, a direct and indirect sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors, with nylidrin, a beta-adrenergic agonist that primarily targets beta-2 receptors to induce peripheral vasodilation, can lead to additive beta-adrenergic stimulation. This synergy increases the risk of cardiovascular adverse effects, including tachycardia, hypertension, myocardial ischemia, and arrhythmias, particularly in patients with pre-existing cardiovascular disease."
"Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), increases systemic norepinephrine levels by inhibiting its reuptake, leading to enhanced sympathetic tone. Ephedrine directly stimulates alpha- and beta-adrenergic receptors and also promotes norepinephrine release from presynaptic terminals. The concurrent elevation of norepinephrine from both mechanisms can synergistically increase heart rate and blood pressure, potentially resulting in severe tachycardia, hypertension, and elevated risk of arrhythmias or myocardial ischemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVOPHED vs EPHEDRINE SULFATE, answered by our medical review team.
LEVOPHED is a Vasopressor that works by Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.. EPHEDRINE SULFATE is a Vasopressor that works by Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVOPHED and EPHEDRINE SULFATE depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVOPHED is: Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.. The standard adult dose of EPHEDRINE SULFATE is: 50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVOPHED and EPHEDRINE SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVOPHED is classified as Category C. Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental . EPHEDRINE SULFATE is classified as Category C. Ephedrine sulfate crosses the placenta. Use in the first trimester is associated with a small increased risk of gastroschisis. In the second and third trimesters, it may cause feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.